Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial - Feagan, BG; Sands, BE; Sandborn, WJ (Lancet Gastroenterol Hepatol, 2023)